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Abstract
Background: S100P is a Ca2+ binding protein overexpressed in a variety of cancers, and thus, has
been considered a potential tumor biomarker. Very little has been studied about its normal
expression and functions.
Methods:  We examined S100P expression in normal human tissues by quantitative reverse
transcription polymerase chain reaction and immunohistochemistry. S100P protein expression was
also studied in a series of tumors, consisting of 74 ovarian, 11 pancreatic, 56 gastric, 57 colorectal,
89 breast and 193 prostate carcinomas using a novel anti-S100P monoclonal antibody.
Results: Among the normal tissues, the highest S100P mRNA levels were observed in the placenta
and esophagus. Moderate signals were also detected in the stomach, duodenum, large intestine,
prostate and leukocytes. At the protein level, the highest reactions for S100P were seen in the
placenta and stomach. Immunostaining of tumor specimens showed that S100P protein is
expressed in all the tumor categories included in the study, being most prevalent in gastric tumors.
Conclusion: Based on our observations, S100P is widely expressed in both normal and malignant
tissues. The high expression in some tumors suggests that it may represent a potential target
molecule for future diagnostic and therapeutic applications.
Background
The S100 proteins belong to the EF-hand superfamily of
Ca2+ binding proteins that mediate Ca2+ dependent signal
transduction pathways involved in the regulation of cell
cycle, growth, differentiation and metabolism [1]. S100
proteins have been functionally associated with various
neurological, cardiac and neoplastic diseases.
S100P protein is a relatively small (95 amino acid) iso-
form of the S100 protein family that was first isolated
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from human placenta [2]. Overexpression of S100P has
been detected in several cancers such as breast [3], colon
[4], prostate [5], pancreatic [6] and lung [7] carcinomas,
and the protein has been functionally implicated in carci-
nogenic processes [8-10]. In pancreatic cancer, S100P is
overexpressed due to hypomethylation of its gene [11].
Studies on prostate cancer have indicated that S100P
expression is regulated by androgens [5] and interleukin-
6 [12]. In gastric cancer cell lines, retinoic acid has been
reported to induce S100P expression [13]. In breast cancer
cell lines, S100P overexpression seems to be an early event
that has been suggested to play a role in the immortaliza-
tion of human breast epithelial cells in vitro and tumor
progression in vivo [3]. In colon cancer cell lines, expres-
sion level of S100P correlated with resistance to chemo-
therapy [14], and in lung and breast cancer to decreased
patient survival [7,15]. However, despite these observa-
tions, little is still known about the functional role or
mechanism of action of S100P. Recently, it has been
shown that S100P can induce anchorage-independence of
tumor cells in vitro and improve tumor growth in a
xenograft model. These results suggested that S100P func-
tionally participates in the control of the tumorigenic
potential in vivo [9].
In the present study, we describe a novel monoclonal anti-
body for S100P protein designated 18-9 and evaluate
S100P expression in normal and neoplastic human tissues
by immunohistochemistry and quantitative reverse tran-
scription-polymerase chain reaction (RT-PCR). This data
could provide valuable information on where S100P is
expressed under normal and pathological conditions, and
whether it could serve as a tissue- or tumor-specific
biomarker.
Methods
Quantitative real-time PCR
The amount of human S100P transcript in different tis-
sues was assessed by quantitative real-time RT-PCR using
the Lightcycler detection system (Roche, Rotkreuz, Swit-
zerland). Real-time PCR primers were designed on the
basis of the complete cDNA sequences deposited in Gen-
Bank (accession number: NM_005980). The primers were
located in two different exons separated by a 2822 bp-
long intron. The sequences were as follows: forward
primer: 5'-TCAAGGTGCTGATGGAGAA-3', reverse
primer: 5'-ACACGATGAACTCACTGAA-3'. Three house-
keeping genes (YWHAZ: Tyrosine 3-monooxygenase/tryp-
tophan 5-monooxygenase activation protein, zeta
polypeptide, GAPD: Glyceraldehyde-3-phosphate dehy-
drogenase, and UBC: Ubiquitin C) were used as internal
RNA controls to normalize the cDNA samples for differ-
ences [16]. The templates for the PCR reactions were
obtained from cDNA kits (human MTC™ digestive panel,
panel I, panel II and blood fractions panel) purchased
from BD Biosciences (Palo Alto, CA). These kits contained
first-strand cDNA preparations produced from poly(A)
RNAs isolated from different organs and cell fractions.
The numbers of pooled tissue specimens for each RNA
sample were as follows: placenta (n = 7), spleen (n = 11),
thymus (n = 18), prostate (n = 32), testis (n = 45), ovary
(n = 5), leukocyte (n = 550), ascending colon (n = 5),
descending colon (n = 7), transverse colon (n = 19), duo-
denum (n = 30), ileocecum (n = 19), ileum (n = 8), jeju-
num (n = 6), rectum (n = 6), cecum (n = 29), stomach (n
= 7), esophagus (n = 39), mononuclear cells (n = 12), rest-
ing CD8+ cells (n = 20), resting CD4+ cells (n = 11), rest-
ing CD14+ cells (n = 36), resting CD19+ cells (pooled
from Caucasian blood donors, number not provided),
activated CD19+ cells (n = 4), activated mononuclear cells
(n = 4), activated CD4+ cells (n = 6) and activated CD8+
cells (n = 8).
Every PCR was performed in a total reaction volume of 20
µl containing 0.5 µl of first strand cDNA, 1× of QuantiTect
SYBR Green PCR Master Mix (Qiagen, Hilden, Germany),
and 0.5 µM of each primer. Amplification and detection
were carried out as follows: After an initial 15-min activa-
tion step at 95°C, amplification was performed in a three-
step cycling procedure: denaturation at 95°C, 15 s, ramp
rate 20°C/s; annealing at the temperature determined
according to the melting temperature for each primer pair
(52°C for S100P, 59°C for YWHAZ and GADP, and 57°C
for UBC), 20 s, ramp rate 20°C/s; and elongation at 72°C,
20 s, ramp rate 20°C/s for 45 cycles and final cooling step.
The melting curve analysis was always performed after the
amplification to check PCR specificity. To quantify the
levels of transcripts for reference genes and S100P in tissue
specimens, a standard curve for each gene was established
using five-fold serial dilutions of known concentrations of
purified PCR products generated from the same primer
sets. Each cDNA sample was tested in duplicate, and the
crossing point (Cp) value obtained allowed us to deter-
mine the amount of the starting message using the specific
standard curve. The geometric mean of the three reference
genes was used as a normalization factor for gene expres-
sion levels [16]. The copy number of S100P in each tissue
was divided by the corresponding normalization factor
and subsequently multiplied by 102.
Antibodies
The monoclonal anti-human S100P antibody 18-9 was
produced by hybridoma technology as follows: Six weeks
old BALB/c mice were immunized by two i.p. inoculations
of GST-S100P fusion protein purified from bacteria trans-
fected with pGEX-3X-S100P plasmid. The plasmid con-
tained the full length S100P cDNA subcloned from the
pSG5C-S100P eukaryotic vector described earlier [9]. The
first immunization dose consisted of 50 µg GST-S100P in
250 µl phosphate-buffered saline (PBS) and 250 µl TiterBMC Clinical Pathology 2008, 8:2 http://www.biomedcentral.com/1472-6890/8/2
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Max Gold adjuvant (Sigma). Three weeks later, the mice
received a challenge in the form of 250 µl suspension of
GST-S100P protein bound to the Glutathione-S Sepha-
rose in absence of adjuvant. The splenocytes were har-
vested after two weeks and fused with the Sp2/0 myeloma
cells. The obtained hybridomas were screened by ELISA
using GST-S100P fusion antigen versus GST alone. Spe-
cific reactivity of the produced monoclonal antibodies
was verified by Western blotting using the cell lines natu-
rally or ectopically expressing S100P. The best hybrido-
mas were subcloned and frozen. The hybridoma clone 18-
9 was expanded and the MAb-containing hybridoma
medium was used for further studies. Another mono-
clonal S100P antibody (control MAb) was purchased
from BD Biosciences Pharmingen (San Diego, CA).
Western blotting
Cells grown in confluent monolayer were rinsed twice
with cold PBS and solubilised in ice-cold RIPA buffer (1%
Triton X-100 and 1% deoxycholate in PBS) containing the
commercial COMPLETE cocktail of protease inhibitors
(Roche Diagnostics GmbH, Mannheim, Germany) for 30
min on ice. The extracts were collected, cleared by centrif-
ugation at 15 000 rpm for 10 min at 4°C and stored at -
80°C. Protein concentrations of the extracts were quanti-
fied using the BCA protein assay reagent (Pierce, Rock-
ford, IL).
The extracts were resolved in 12% SDS-PAGE and trans-
ferred to PVDF membrane (Amersham Pharmacia Bio-
tech, Little Chalfont Buckinghamshire, UK). After
blocking in 5% non-fat dry milk with 0.2% Nonidet P40
in PBS, the membrane was probed with the MAb 18-9,
washed and treated with secondary anti-mouse HRP-con-
jugated swine antibody diluted 1/7500 (Sevapharma,
Prague, Czech Republic). The protein bands were visual-
ized by enhanced chemiluminescence using the ECL kit
(Amersham Pharmacia Biotech).
Reverse transcription PCR
Total RNA was isolated from the cell monolayers using the
INSTAPURE solution (Eurogentech, Belgium) according
to the protocol of the manufacturer. Reverse transcription
was performed with Mo-MuLV reverse transcriptase
(Finnzymes OY, Espoo, Finland) as described before [9].
RT-PCR was performed with Taq DNA polymerase
(Finnzymes) in an automatic DNA thermal cycler (Eppen-
dorf AG, Hamburg, Germany). Following an initial dena-
turation at 95°C for 3 min, the amplification program was
set as follows: denaturation at 95°C for 30 sec, annealing
at 60°C for 30 sec, and extension at 72°C during 40 sec
for a total of 30 cycles, and finally 5 min at 72°C. Result-
ing PCR fragments were run on 2% agarose gels. The
nucleotide sequences of the primers were as follows (s,
sense; a, antisense): S100P-s (109-130) 5'-AAG-
GGGGAGCTCAAGGTGCTGA-3', S100P-a (330-308) 5'-
ATCTGTGACATC TCCAGGGCATC-3', S100A4-s 5'-
GCAAAGAGGGTGACAAGTTCAAG-3', S100A4-a 5'-GAT-
GCAGGACAGGAAGACACAGT-3'.
Immunohistochemistry
The normal tissue and tumor specimens were collected at
Oulu and Tampere University Hospitals. The tumor mate-
rials included 74 ovarian, 11 pancreatic, 56 gastric, 57
colorectal, 89 breast and 193 prostate carcinomas. All tis-
sue samples were obtained during surgery according to
the guidelines of the Declaration of Helsinki and proc-
essed for routine histopathological evaluation. Collection
of specimens was approved by the local ethics commit-
tees. The specimens were first fixed in 4% neutral-buffered
formaldehyde, dehydrated in ethanol series, treated with
xylene and mounted in paraffin.
Automated immunostaining for S100P was performed
using Power Vision+™ Poly-HRP IHC Kit reagents (Immu-
noVision Technologies, Co.). The immunostaining
method included the following steps: (a) deparaffiniza-
tion of the sections using xylene and ethanol series; (b)
treatment with Tris-EDTA buffer, pH 9.0, at 105°C for 15
min; (c) rinsing in wash buffer (Tris-buffered saline, pH
7.6, containing 0.05% Tween-20); (d) incubation with
18-9 monoclonal anti-S100P antibodies diluted 1:20 in
Universal IHC Blocking/Diluent for 30 min; (e) rinsing in
wash buffer; (f) blocking with Universal IHC Blocking/
Diluent for 20 min; (g) rinsing in wash buffer; (h) incuba-
tion in Poly-HRP-conjugated anti-rabbit/mouse IgG for
30 min and rinsing in wash buffer; (i) incubation in DAB
(3,3'-diaminobenzidine tetrahydrochloride) solution
(one drop DAB solution A and one drop DAB solution B
with 1 ml ddH2O) for 5 min; (j) rinsing with ddH2O; (k)
0.5% CuSO4 treatment for 5 min to enhance the signal; (l)
rinsing with wash buffer; (m) counterstaining with hema-
toxylin solution for 2 min; and (n) rinsing with ddH2O.
All procedures except for the step (b) were carried out at
room temperature. The sections were mounted in Entel-
lan Neu (Merck; Darmstadt, Germany) and finally exam-
ined and photographed with a Zeiss Axioskop 40
microscope (Carl Zeiss; Göttingen, Germany).
Results
S100P mRNA expression
In our study, we first performed quantitative RT-PCR to
analyze S100P mRNA levels in various normal human tis-
sues. The PCR product from placenta was sequenced in
order to confirm its identity and to exclude any unspecific
binding of primers (data not shown). Figure 1A demon-
strates that positive signals for S100P mRNA were detect-
able in most tissues. The highest expression levels were
found in the placenta (~90.4 times the housekeeping gene
expression levels). The esophagus also showed relativelyBMC Clinical Pathology 2008, 8:2 http://www.biomedcentral.com/1472-6890/8/2
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high expression (~6.7 times the housekeeping gene
expression levels). Other segments of the gastrointestinal
canal including the stomach, duodenum and large intes-
tine showed moderate mRNA levels which were lower or
slightly higher compared to the housekeeping genes. The
jejunum and ileum demonstrated almost negligible levels
of expression. From the reproductive tract organs the pros-
tate was moderately positive, whereas both ovary and tes-
tis displayed extremely low signals. Lymphatic tissues
including the spleen and thymus as well as leukocytes
were positive, but the expression levels remained lower
compared to the housekeeping genes. We further ana-
lyzed different fractions of the human leukocytes for
S100P expression (Fig 1B). The highest mRNA expression
was detected in resting CD14+ cells representing the
monocyte fraction of the blood cells. Unstimulated T-cells
(CD4+ and CD8+) exhibited very weak signals which
became slightly higher in activated cells.
S100P protein expression
In addition to the mRNA analysis, we wanted to elucidate
S100P protein expression by immunohistochemistry in
various human tissues. For this purpose, we used a newly
generated anti-S100P monoclonal antibody 18-9 pro-
duced against a recombinant fusion GST-S100P antigen.
First, we verified the specificity of the MAb (Fig. 2). In
Western blotting, 18-9 MAb reacted well with the purified
GST-S100P protein, but not with the GST alone. The MAb
also recognized an 11 kDa protein in HeLa cells and HeLa-
R cells transfected with S100P cDNA, whereas no protein
was detected in MDA-MB 231 cells and mock-transfected
HeLa-R cells (Fig. 2A). These negative cell lines do not
express S100P, but show expression of S100A4, as
described previously [9,15,17] and also clearly demon-
strated in Figure 2B by RT PCR.
The specificity of the 18-9 MAb was also evaluated by
immunohistochemistry in comparison with the control
MAb in parallel sections of the human stomach antrum
(Fig. 3). Both antibodies revealed strong positive immu-
noreactions in the surface epithelial cells. The control
MAb showed slightly stronger reactivity in the glands and
lamina propria. All these results clearly demonstrated that
the 18-9 MAb is specific for S100P protein and approved
its use for the immunohistochemical analysis of S100P
expression in human tissues (Figs 4 and 5) and carcino-
mas including breast (Fig. 6A,B), gastric (Fig. 6C), pancre-
atic (Fig. 6D), ovarian (Fig. 6E,F), prostate, and colon (Fig.
7) tumors. Immunohistochemical results indicated that
the placenta indeed expresses very high levels of S100P
protein in trophoblast cells (Fig. 4A,B). In the placenta as
well as in all other positive tissues, the immunoreactions
were strongest in the nuclei and weaker intracellular stain-
ing was also detectable. The normal gastric epithelium
was another site which showed high immunoreactivity for
S100P protein (Fig. 4C,D). In the body of the stomach,
the immunostaining was localized to the mucus produc-
ing surface epithelial cells and chief cells of the gastric
glands. Intestinal metaplasia was occasionally observed in
some specimens of the gastric mucosa. The normal epithe-
lium showed stronger immunostaining than the meta-
plastic epithelium (Fig. 4E). Esophageal mucosa showed
immunopositivity which was mainly located to the most
superficial epithelial cells (Fig. 4F). The pancreas and liver
were mainly negative for S100P (Fig. 2G,H). In these tis-
Relative S100P mRNA expression levels in normal human tis- sues and leukocyte fractions Figure 1
Relative S100P mRNA expression levels in normal human tis-
sues and leukocyte fractions. Value 100 indicates the geomet-
ric mean of the expression levels of three housekeeping 
genes used in the study.BMC Clinical Pathology 2008, 8:2 http://www.biomedcentral.com/1472-6890/8/2
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sues, some positive cell nuclei were occasionally associ-
ated with blood vessels, and by histological examination
these cells were identified as granulocytes.
Various segments of the intestine were also dissected for a
more detailed immunohistochemical analysis. The results
indicated that all segments of the large intestine including
cecum, colon and rectum (data not shown) were positive
(Fig. 5C,D). The highest immunoreactions were localized
in the epithelial cells of the superficial epithelial cuff
region, while the reactions became weaker toward the
crypts. In the duodenum, positively stained nuclei were
quite frequently present in the enterocytes (Fig. 5A), and
positive reactions were also detectable in the jejunum and
ileum (Fig. 5B) which showed very low mRNA levels (Fig.
1A). Both lymphoid follicles and smooth muscle of the
intestinal wall were negative (Fig. 5E,F). Figure 6 demon-
strates S100P protein expression in different malignant
tumors including breast, gastric, pancreatic and ovarian
carcinomas. Figure 7 shows the staining results in some
colorectal carcinomas and benign specimens obtained
from the same patients. These figures indicate that the
staining reactivity was higher in most tumors (54%) com-
pared to the adjacent benign tissue. It also varied within
each tumor category, which is demonstrated in breast
(Fig. 6A,B) and ovarian (Fig. 6E,F) carcinomas. The
immunostaining results are summarized in Figure 8. Gas-
tric carcinomas showed the strongest immunoreactions,
almost half of the specimens having strong signals. From
these tumors, the lowest staining reactions were observed
in breast, prostate and ovarian cancers. In the tumor cate-
gories studied, the expression of S100P showed no corre-
lation to the tumor grade (data not shown).
Discussion
S100P protein has been recently considered a potential
biomarker of cancer due to its frequent expression in dif-
ferent types of tumor tissues [18,19]. Moreover, its direct
implication in cancer biology has been proposed on the
basis of the experimental data obtained with S100P-trans-
fected tumor cells in vitro and in vivo as well as of the data
from various gene array studies [8,9,15,20-22].
In the present study, we used a newly generated anti-
S100P monoclonal antibody 18-9 for immunohisto-
chemical analysis of S100P expression in a series of nor-
mal and tumor human tissues. The comparative analysis
of the new 18-9 MAb and the commercial control MAb
confirmed that these two MAbs are both specific for
S100P protein, but bind to different epitopes (data not
shown). The immunoreactions obtained with two differ-
ent S100P antibodies in parallel sections showed that the
MAb 18-9 and the commercially available antibody recog-
nize the same cell types in most cases and the subcellular
distribution of the immunoreaction is similar. Both anti-
bodies showed the highest immunoreaction in the cell
nuclei. In addition, positive intracellular reactions were
observed, which most probably reflects either the newly
Specific detection of S100P with 18-9 MAb Figure 2
Specific detection of S100P with 18-9 MAb. A, Western blotting analysis of the recombinant GST-S100P protein versus GST 
alone and of S100P protein in extracts from MDA-MB 231 breast carcinoma cells, HeLa cervical carcinoma cells, HeLa-R vari-
ant cells with reduced tumorigenicity [9], and HeLa-R cells transfected with S100P cDNA. B, RT PCR analysis of the same cell 
lines for the expression of S100P and S100A4 genes, respectively.BMC Clinical Pathology 2008, 8:2 http://www.biomedcentral.com/1472-6890/8/2
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produced protein in the cytosolic compartment of the cell
or the fraction of S100P molecules that interact with F-
actin-binding protein ezrin [23]. The main difference
between these antibodies was detectable in the glands of
the gastric mucosa, which seemed to produce slightly
higher background staining by the commercial antibody.
Based on the immunostaining and quantitative RT-PCR
results, the placenta clearly showed the most prominent
expression among all normal tissues. The second most
prominent immunostaining was observed in the gastric
mucosa. For an unknown reason the mRNA levels in the
stomach were comparable to several other segments of the
gastrointestinal canal and distinctly lower than in the
esophagus which repeatedly showed high mRNA signals
and relatively weak or moderate immunohistochemical
staining. These inconsistencies between the mRNA and
protein levels might reflect tissue type-related differences
in secretion of S100P protein to extracellular space, where
it appears to function as a signalling molecule via activa-
tion of RAGE receptor [24]. Alternatively, they may sug-
Immunohistochemical localization of S100P protein in normal  human tissues Figure 4
Immunohistochemical localization of S100P protein in normal 
human tissues. Panel A shows the staining reaction obtained 
by new 18-9 MAb in the placenta. Commercial control S100P 
antibody has been used in the panel B. Both antibodies immu-
nostain trophoblast cells (arrowheads in the inset) lining the 
placental villi. Other panels demonstrate the distribution of 
S100P protein in the human gastric mucosa (C,D,E), esopha-
gus (F), liver (G) and pancreas (H). The staining reactions are 
strong in the stomach, distinctly weaker in the esophagus and 
negative in the liver and pancreas. In the stomach, the most 
prominent signals were located to the mucus secreting epi-
thelial cells. Positive reactions were also present in the prin-
cipal cells (small arrows) of the gastric glands (GL). The 
parietal cells were negative or only weakly stained (small 
arrowheads). The large arrows in panel E point to the intesti-
nal metaplasia that was occasionally seen in some specimens 
as a benign pathological change within the gastric mucosa. In 
panel F, the arrowheads indicate some positive nuclei in the 
esophageal epithelium. EN = endocrine pancreas, EX = exo-
crine pancreas.
Immunohistochemical comparison of the reactivity of 18-9  MAb (A) versus control MAb (B) in parallel sections of the  gastric antrum Figure 3
Immunohistochemical comparison of the reactivity of 18-9 
MAb (A) versus control MAb (B) in parallel sections of the 
gastric antrum. In both panels, the highest immunoreactivity 
is located in the surface epithelial cells. Control MAb shows 
slightly higher staining in the glands (GL) and lamina propria 
(asterisk).BMC Clinical Pathology 2008, 8:2 http://www.biomedcentral.com/1472-6890/8/2
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gest tissue-specific variations in posttranscriptional
regulation of S100P expression or in turnover of S100P
protein.
Structural studies have shown that S100P protein exists as
a dimer and the S100P homodimer is probably more sta-
ble than those of other S100 proteins [25]. High stability
is a prerequisite for a good biomarker. In this respect,
S100P gene or protein expression has already been proved
to correlate with patient survival in lung [7,26] and breast
cancer [15], and it has been proposed as an early develop-
mental marker of pancreatic carcinogenesis [19]. Our
present results using a newly generated monoclonal
S100P antibody confirmed the expression of S100P pro-
tein in several tumor categories. It is noteworthy, how-
ever, that S100P is not restricted to neoplastic cells, but is
also detectable in various normal cell types. This fact has
to be carefully considered when planning novel diagnos-
tic and therapeutic applications based on S100P expres-
sion.
Conclusion
The present immunohistochemical and quantitative RT-
PCR results demonstrate that S100P protein is widely
expressed in both normal and neoplastic tissues. It clearly
shows ectopic expression in some cancers. Based on the
high expression in certain tumors, S100P could represent
a potential target for novel diagnostic and therapeutic
applications.
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